CARM1 and ovarian cancer: This study suggests that high levels of NAC1 and CARM1 are associated with poor prognosis in ovarian cancer patients receiving adjuvant chemotherapy, providing a new direction for prognostic biomarkers predicting chemotherapy resistance in ovarian cancer.